Research programme: nephritis therapy - ChemoCentryx
Latest Information Update: 01 Dec 2022
At a glance
- Originator ChemoCentryx
- Class Small molecules
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nephritis
Most Recent Events
- 11 Jul 2003 Preclinical trials in Nephritis in USA (unspecified route)